Clorox
CLX
82.21
-1.31
-1.57%
Clorox
US · CLX
#1495 by market cap
Listed 1970
82.21
-1.31
-1.57%
Live - 5344 symbols - heartbeat 278s ago
· 2026-10-08 07:00
Pre-market
82.35
+0.16%
After-hours
82.43
+0.27%
Overnight
81.77
-0.54%
- Market cap
- 9.94B
- P/E (TTM)i
- 17.09
- P/Bi
- 110.50
- EPSi
- 4.81
- Div yieldi
- 6.03%
- 52W posi
- 7%
Reader sentiment
Are you bullish or bearish on CLX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 1.95, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -5.41% YoY
Margins
- Gross margin
- 42.32%
- Operating margin
- 13.18%
- Net margin
- 8.74%
Key ratios & quality
- Enterprise valuei
- 14.95B
- PEG ratioi
- 0.29
- Altman Z-Scorei
- 1.95
PEG uses trailing P/E against the 3-year net income growth rate (57.94%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6.21B | 6.72B | 7.34B | 7.11B | 7.39B | 7.09B | 7.10B | 6.72B |
| Gross profit | 2.73B | 3.06B | 3.20B | 2.55B | 2.91B | 3.05B | 3.21B | 2.84B |
| Selling & admin expenses | 1.47B | 1.64B | 1.79B | 1.66B | 1.92B | 2.17B | 1.89B | 1.82B |
| Research & development | 136.00M | 145.00M | 149.00M | 132.00M | 138.00M | 126.00M | 121.00M | 116.00M |
| Operating profit | 1.11B | 1.26B | 1.23B | 719.00M | 823.00M | 723.00M | 1.18B | 886.00M |
| Pretax profit | 1.02B | 1.19B | 900.00M | 607.00M | 238.00M | 398.00M | 1.08B | 791.00M |
| Tax | 204.00M | 246.00M | 181.00M | 136.00M | 77.00M | 106.00M | 254.00M | 190.00M |
| Net profit | 820.00M | 939.00M | 719.00M | 471.00M | 161.00M | 292.00M | 824.00M | 601.00M |
| Basic EPS | 6 | 7 | 6 | 4 | 1 | 2 | 7 | 5 |
| Diluted EPS | 6.32 | 7.36 | 5.58 | 3.73 | 1.20 | 2.25 | 6.52 | 4.81 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.67B | 1.99B | 1.43B | 1.67B | 1.67B | 1.95B |
| Gross profit | 744.00M | 924.00M | 596.00M | 722.00M | 722.00M | 804.00M |
| Selling & admin expenses | 474.00M | 467.00M | 443.00M | 452.00M | 406.00M | 514.00M |
| Research & development | 27.00M | 32.00M | 28.00M | 29.00M | 27.00M | 32.00M |
| Operating profit | 238.00M | 420.00M | 120.00M | 236.00M | 284.00M | 246.00M |
| Pretax profit | 254.00M | 410.00M | 107.00M | 215.00M | 256.00M | 213.00M |
| Tax | 63.00M | 74.00M | 25.00M | 54.00M | 65.00M | 46.00M |
| Net profit | 191.00M | 336.00M | 82.00M | 161.00M | 191.00M | 167.00M |
| Basic EPS | 2 | 3 | 1 | 1 | 2 | 1 |
| Diluted EPS | 1.50 | 2.68 | 0.65 | 1.29 | 1.54 | 1.34 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.31B | 2.02B | 1.83B | 1.73B | 1.83B | 1.62B | 1.61B | 1.82B |
| Cash & ST investments | 111.00M | 871.00M | 319.00M | 183.00M | 367.00M | 202.00M | 167.00M | 143.00M |
| Inventory | 512.00M | 454.00M | 752.00M | 755.00M | 696.00M | 637.00M | 523.00M | 777.00M |
| Total assets | 5.12B | 6.21B | 6.33B | 6.16B | 5.95B | 5.75B | 5.56B | 7.79B |
| Total current liabilities | 1.44B | 1.42B | 2.06B | 1.78B | 1.92B | 1.57B | 1.92B | 2.77B |
| Short-term debt | 396.00M | 64.00M | 381.00M | 315.00M | 137.00M | 88.00M | 91.00M | 1.17B |
| Long-term debt | 2.29B | 2.78B | 2.48B | 2.47B | 2.48B | 2.48B | 2.48B | 3.98B |
| Total liabilities | 4,557,000,000.00 | 5,305,000,000.00 | 5,742,000,000.00 | 5,429,000,000.00 | 5,557,000,000.00 | 5,259,000,000.00 | 5,079,000,000.00 | 7,542,000,000.00 |
| Total equity | 559.00M | 908.00M | 592.00M | 729.00M | 388.00M | 492.00M | 482.00M | 252.00M |
| Retained earnings | 3.15B | 3.57B | 1.04B | 1.05B | 583.00M | 250.00M | 432.00M | 386.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.59B | 1.61B | 1.70B | 1.73B | 2.65B | 1.82B |
| Cash & ST investments | 226.00M | 167.00M | 166.00M | 227.00M | 1.19B | 143.00M |
| Inventory | 635.00M | 523.00M | 577.00M | 608.00M | 588.00M | 777.00M |
| Total assets | 5.51B | 5.56B | 5.53B | 5.61B | 6.44B | 7.79B |
| Total current liabilities | 2.16B | 1.92B | 2.23B | 2.35B | 3.16B | 2.77B |
| Short-term debt | 139.00M | 91.00M | 307.00M | 390.00M | 1.68B | 1.17B |
| Long-term debt | 2.48B | 2.48B | 2.49B | 2.49B | 2.49B | 3.98B |
| Total liabilities | 5,322,000,000.00 | 5,079,000,000.00 | 5,390,000,000.00 | 5,578,000,000.00 | 6,344,000,000.00 | 7,542,000,000.00 |
| Total equity | 190.00M | 482.00M | 138.00M | 35.00M | 92.00M | 252.00M |
| Retained earnings | 99.00M | 432.00M | 200.00M | 190.00M | 223.00M | 386.00M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 992.00M | 1.55B | 1.28B | 786.00M | 1.16B | 695.00M | 981.00M | 612.00M |
| Depreciation & amortization | 180.00M | 180.00M | 211.00M | 224.00M | 236.00M | 235.00M | 219.00M | 247.00M |
| Free cash flow | 786.00M | 1.29B | 945.00M | 535.00M | 930.00M | 483.00M | 761.00M | 405.00M |
| Dividends paid | -490.00M | -533.00M | -558.00M | -571.00M | -583.00M | -595.00M | -602.00M | -602.00M |
| Stock buybacks / issuance | -661.00M | -248.00M | -905.00M | -25.00M | 0 | 0 | -332.00M | -256.00M |
| Ending cash balance | 113.00M | 879.00M | 324.00M | 186.00M | 368.00M | 207.00M | 170.00M | 147.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 286.00M | 294.00M | 93.00M | 311.00M | -122.00M | 330.00M |
| Depreciation & amortization | 55.00M | 57.00M | 56.00M | 55.00M | 58.00M | 78.00M |
| Free cash flow | 233.00M | 219.00M | 57.00M | 269.00M | -165.00M | 244.00M |
| Dividends paid | -150.00M | -150.00M | -151.00M | -151.00M | -150.00M | -150.00M |
| Stock buybacks / issuance | 0 | -75.00M | -129.00M | -127.00M | 0 | 0 |
| Ending cash balance | 229.00M | 170.00M | 169.00M | 229.00M | 1.19B | 147.00M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 127.63 | 128.02 | 107.66 | 95.55 | 38.40 | 102.19 | 249.61 | 285.64 |
| ROA %i | 16.12 | 16.58 | 11.32 | 7.40 | 2.46 | 4.79 | 14.32 | 8.79 |
| ROIC %i | 27.76 | 27.94 | 20.64 | 14.94 | 5.85 | 10.33 | 27.06 | 15.43 |
| 5-year avg ROE %i | 232.66 | 172.97 | 132.04 | 117.73 | 99.45 | 94.36 | 118.68 | 154.28 |
| EBIT margin %i | 18.04 | 19.10 | 13.61 | 10.03 | 4.44 | 6.88 | 16.41 | 13.71 |
| FCF / sales %i | 12.65 | 19.22 | 12.87 | 7.53 | 12.59 | 6.81 | 10.71 | 6.03 |
| Current ratioi | 0.91 | 1.42 | 0.89 | 0.97 | 0.95 | 1.03 | 0.84 | 0.66 |
| Quick ratioi | 0.52 | 1.07 | 0.45 | 0.48 | 0.55 | 0.57 | 0.51 | 0.34 |
| Debt / assetsi | 52.44 | 50.25 | 49.98 | 50.39 | 49.18 | 50.48 | 51.79 | 70.82 |
| LT debt / equityi | 409.12 | 336.78 | 677.62 | 501.44 | 1,266.82 | 858.23 | 868.85 | 4,830.00 |
| Interest coveragei | 11.56 | 12.97 | 10.09 | 6.73 | 3.64 | 5.42 | 13.25 | 7.08 |
| Revenue CAGR (3Y) %i | 2.56 | 4.01 | 6.23 | 4.58 | 3.21 | -1.14 | -0.01 | -3.11 |
| Net income CAGR (3Y) %i | 8.16 | 10.23 | -4.80 | -17.41 | -45.86 | -26.67 | 20.58 | 57.94 |
| FCF CAGR (3Y) %i | 9.06 | 26.78 | 6.51 | -12.03 | -10.38 | -20.05 | 12.46 | -24.20 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 1,176.27 | 249.61 | 4,163.16 | -- | -- | 285.64 |
| ROA %i | 12.26 | 14.32 | 14.35 | 13.49 | 12.65 | 8.79 |
| ROIC %i | 24.75 | 27.06 | 28.54 | -- | -- | 15.43 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 14.67 | 16.41 | 16.22 | 15.97 | 16.05 | 13.71 |
| FCF / sales %i | 11.41 | 10.71 | 9.39 | 11.51 | 5.62 | 6.03 |
| Current ratioi | 0.74 | 0.84 | 0.76 | 0.74 | 0.84 | 0.66 |
| Quick ratioi | 0.38 | 0.51 | 0.39 | 0.38 | 0.59 | 0.34 |
| Debt / assetsi | 53.41 | 51.79 | 55.68 | 57.31 | 69.70 | 70.82 |
| LT debt / equityi | 10,388.89 | 868.85 | -- | -- | -- | 4,830.00 |
| Interest coveragei | 11.84 | 13.25 | 12.20 | 11.60 | 11.19 | 7.08 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Health and wellness is the largest reported line at 40.13% of revenue, across 4 reported segments.
- No single line clears half of revenue; Household is next at 26.59%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Health and wellness40.13%
Household26.59%
Lifestyle16.71%
International16.56%
Region
United States83.76%
Foreign16.24%
Quote time 2026-10-08 07:00:09 · For reference only, not investment advice and not tailored to your situation.